Mark C. Poznansky, MD, PhD
Dr. Poznansky has gained national and international recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. He oversees the research work of a large team of investigators, postdoctoral fellows and other trainees addressing key research questions regarding new therapeutics and vaccines and leads an operational team that facilitates the execution of business, regulatory, manufacturing, and other product development tasks associated with the preclinical translation of these candidates. Dr. Poznansky is also dedicated to the training and mentoring of minority scientists and has been actively involved in both the Center for Diversity and Inclusion at MGH, the Boston Science Careers Program and a URM student program that we have run at VIC and in my laboratory for over 15 years.
He was awarded a Harrison Watson Fellowship to do his PhD at Clare College, Cambridge University and a Harkness Fellowship to do postdoctoral studies in the USA. While in the UK he also served as a Captain in the Royal Army Medical Corps (V). He completed his post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute. He completed his infectious diseases fellowship training at Imperial College in London and at Harvard Medical School.
Outside of VIC
Dr. Poznansky is the scientific founder of five biotech companies and served as the Co-Director of the Medicine Innovation Program at MGH and currently serves as a member of the Partners Commercialization Council. He was recently honored as one of the Cancer-One Hundred by the MGH Cancer Center for contributions to the development of new vaccines and immunotherapies for cancer and a Partners in Excellence Award for his clinical services to MGH. He is a scientific advisor to several organizations and serves on the grant review board for the JDRF.